Semaglutide

Semaglutide acts on the GLP-1 pathway involved in appetite and glucose regulation. Large human trials of defined medicines have demonstrated weight reduction in specified populations; the study summaries explain the magnitude, duration and limitations.

Research focus & potential applications

Appetite regulation

Metabolic health research

What the research shows

Explore the selected studies, their findings and their limits.

Read the findings & sources

Human study discussed

STEP 1 randomized 1,961 adults with overweight or obesity without diabetes. At 68 weeks, mean body-weight reduction was 14.9% with the studied semaglutide treatment versus 2.4% with placebo, with lifestyle support in both groups. Nausea and diarrhea were common; gastrointestinal events led to more treatment discontinuations. These are trial averages for a defined medicine and population, not predicted results from an AUREVIX preparation.

PubMed · 33567185

For more information, contact info@aurevixpeptides.com.

Editorial review: September 23, 2026